



## Mydecine Announces Debt Settlement Transaction

DENVER, Colorado, USA, September 21, 2020 -- [Mydecine Innovations Group, Inc.](#), (CSE:MYCO) (OTC:MYCOF) (FSE:ONFA) ("Mydecine", "MIG" or the "Company") announces that its board of directors has approved the settlement of a principal amount of \$15,600.00 in debt for services rendered through the issuance of common shares (the "Debt Settlement"). Pursuant to the Debt Settlement, the Company issued 74,286 common shares of the Company (the "Shares") at a deemed price of \$0.21 per Share to a creditor of the Company. All securities issued will be subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance.

The Company further announces that on September 16, 2020, it cancelled and returned to treasury 529,034 Shares that were originally issued to a former consultant of the Company on May 7, 2020 (the "Share Cancellation"). Following the Debt Settlement and Share Cancellation, the issued and outstanding common shares of the Company is 162,724,412.

### About Mydecine Innovations Group Inc.

[Mydecine Innovations Group™](#) is a publicly traded life sciences parent company with offices in Denver, CO and Vancouver, BC. Mydecine™ is dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine's experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system design, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and functional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

For further information about Mydecine Innovations Group Inc., please visit the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) or visit the Company's website at [www.mydecine.com](http://www.mydecine.com).

### On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer  
[contact@mydecineinc.com](mailto:contact@mydecineinc.com)

### Corp Communication:

Charles Lee, Investor Relations  
[corp@mydecineinc.com](mailto:corp@mydecineinc.com)

### Public Relations:

Cynthia Salarizadeh, Public Relations  
[pr@mydecineinc.com](mailto:pr@mydecineinc.com)

**The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.** This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property,



the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.